

## COVID 19 TEST – VALIDATION OUTCOME

2 March 2021  
Assi Askala  
Acon Laboratories Inc

TC/HR/010321

Dear Assi Askala

### **COVID 19 TEST - VALIDATION OUTCOME**

Thank you for your ongoing co-operation and for providing us with the samples of the FlowFlex SARS-CoV-2 Antigen Rapid Test that we requested for validation.

Your product progressed through phase 3A validation and has been examined at a Design Authority Review (DAR). We would like to advise you that the FlowFlex SARS-CoV-2 Antigen Rapid Test was successful in the phase 3A validation and that the FlowFlex SARS-CoV-2 Antigen Rapid Test showed no drop off in sensitivity when compared with the wild type with respect to the following variants - VOC1 Kent, UK, B.1.1.7 and VOC2 South Africa, B.1.351.

We will continue to evaluate the FlowFlex SARS-CoV-2 Antigen Rapid Test against future variants as and when they arise and we will report the results of any future validation to you.

### **CONFIDENTIALITY**

We remind you of your ongoing obligations of confidentiality as set out in the non-disclosure agreement signed by you dated 29 October 2020.

We thank you for your continued interest in supporting our COVID-19 response

Yours sincerely,

NHS Test and Trace

Enc: Phase 3A validation result FlowFlex SARS-CoV-2 Antigen Rapid Test